Ratings Harrow, Inc.

Equities

HROW

US4158581094

Real-time Estimate Cboe BZX Other stock markets 03:33:44 2024-05-14 pm EDT			5-day change	1st Jan Change
16.86 ^USD	+39.69%		+52.65%	+49.11%

02:00pm	Transcript : Harrow, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 13	Harrow Health Q1 Core Net Loss Widens, Revenue Increases -- Shares Rise After-Hours	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
HARROW, INC.	+49.11%	427M	C-
ELI LILLY AND COMPANY	+30.93%	682B	C+
NOVO NORDISK A/S	+30.35%	586B	B
JOHNSON & JOHNSON	-3.49%	364B	C+
MERCK & CO., INC.	+18.17%	327B	B-
ABBVIE INC.	+4.07%	285B	C+
ASTRAZENECA PLC	+15.53%	240B	B+
NOVARTIS AG	+10.16%	209B	B-
ROCHE HOLDING AG	-8.14%	203B	A+
AMGEN INC.	+8.22%	165B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders